Best Hospitals for Endometriosis Treatment in Delhi NCR, India

Endometriosis is a chronic, estrogen-dependent inflammatory condition in which endometrial-like tissue implants and proliferates outside the uterine cavity — most commonly on the ovaries, fallopian tubes, peritoneum, uterosacral ligaments, rectovaginal septum, bladder, and, in severe cases, the bowel and ureters. These ectopic lesions undergo cyclic hormonal stimulation analogous to the eutopic endometrium, generating localized inflammation, fibrosis, adhesion formation, and progressive pelvic organ distortion. The disease is staged using the revised American Society for Reproductive Medicine (rASRM) classification (Stage I–IV) as well as the more clinically nuanced Enzian classification for deep infiltrating endometriosis (DIE), which better predicts surgical complexity and fertility outcomes.

• Women aged 18–50 experiencing chronic pelvic pain, dysmenorrhea, dyspareunia, or subfertility unresponsive to first-line analgesics or oral contraceptives
• Patients with ultrasound- or MRI-confirmed ovarian endometriomas (≥3 cm), deep infiltrating endometriosis, or extensive pelvic adhesions
• Women with documented subfertility (≥12 months) where endometriosis is the suspected or confirmed contributing factor, considering fertility-preserving excision prior to IVF
• Patients with rASRM Stage III–IV disease, Enzian Class B or C DIE involving the bowel wall, ureter, or bladder requiring multidisciplinary surgical planning
• Individuals who have failed or are intolerant to hormonal therapies (combined oral contraceptives, progestin-only therapy, GnRH agonists such as leuprolide acetate, or GnRH antagonists such as elagolix/relugolix)
• +1 more

Required Pre-Operative Diagnostics:

• Transvaginal Ultrasound (TVUS) by an endometriosis-specialist sonographer using specific sliding sign protocols for DIE mapping
• Pelvic MRI with bowel preparation (MRI enterography protocol) for comprehensive DIE mapping including rectovaginal, bladder, and ureteral involvement
• Anti-Müllerian Hormone (AMH) and Antral Follicle Count (AFC) for ovarian reserve assessment prior to endometrioma surgery
• CA-125 serum level (useful as a monitoring biomarker; not diagnostic in isolation)
• Renal ultrasound or CT urogram if ureteral involvement is suspected on MRI
• +2 more

Medical (hormonal) MANAGEMENT:

Hormonal suppression targets the estrogen-dependent proliferation of ectopic lesions. First-line agents include combined oral contraceptives (COCs) used cyclically or continuously and progestin-only preparations (norethindrone acetate, dienogest — the latter showing superior lesion-specific efficacy). Second-line therapies include GnRH agonists (leuprolide acetate depot, goserelin, nafarelin) inducing a hypoestrogenic state with add-back therapy to mitigate bone loss. Newer-generation oral GnRH antagonists — elagolix (Orilissa) and relugolix/estradiol/norethindrone acetate (Myfembree) — offer dose-titratable estrogen suppression with faster onset and offset, without the initial flare effect of GnRH agonists. The levonorgestrel-releasing intrauterine system (LNG-IUS / Mirena) is an effective long-term option for adenomyosis-associated or superficial peritoneal disease. Aromatase inhibitors (letrozole, anastrozole) in combination with progestins or COCs are reserved for refractory or postmenopausal disease.

Surgical Management — Standard Laparoscopic APPROACH:

Diagnostic and operative laparoscopy is the gold standard for definitive diagnosis and initial surgical treatment. Superficial peritoneal implants can be managed by electrosurgical ablation (monopolar or bipolar), laser vaporization (CO2 laser), or cold excision. However, excision is strongly preferred over ablation as it provides histological confirmation, removes the full depth of the lesion, and reduces recurrence rates. Ovarian endometriomas are treated via laparoscopic cystectomy (stripping technique) with meticulous attention to preserving surrounding healthy ovarian cortex to protect ovarian reserve. Adhesiolysis restores normal pelvic anatomy and improves fertility outcomes.

PHASE 1 — Pre-arrival (4–8 WEEKS Before TRAVEL):

• Submit medical records, operative reports, imaging (MRI/TVUS), hormonal profiles, and CA-125 to GAF Healthcare's coordination team
• GAF's partner gynecologic surgeons conduct a digital case review and provide a personalized surgical plan (laparoscopic excision, robotic DIE, or multidisciplinary bowel/urological case)
• Receive a detailed cost estimate, hospital admission timeline, and pre-operative optimization protocol
• Apply for Indian e-Medical Visa (processed within 72 hours via GAF's support) or confirm UAE tourist/medical visa status
• Pre-operative instructions: bowel preparation protocol (for DIE/bowel cases), cessation of NSAIDs and anticoagulants 5–7 days prior, hormonal therapy adjustment as directed by surgeon

PHASE 2 — Arrival & Pre-operative Workup (DAY 1–2):